RCS - Oxford Biomedica PLC - OXB to present at Leerink Conference

Oxford BioMedicaAnnouncement

26/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250226:nRSZ4500Ya&default-theme=true

RNS Number : 4500Y  Oxford Biomedica PLC  26 February 2025

 

 

 

OXB to present at the Leerink Partners Global Healthcare Conference

Oxford, UK - 26 February 2025: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda
Crabtree, Chief Financial Officer, will take part in a fireside chat at the
Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11
March 2025 at 2:20 PM EDT / 6:20 PM GMT.

A live webcast of the fireside chat will be available on the 'Investor
Relations' section of OXB's website under 'Results, Reports, Presentations
& Webcasts' at www.oxb.com (http://www.oxb.com) . A replay will be
accessible following the event.

-Ends-

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com (mailto:ir@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities span
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGZGZZMKFGKZZ